Stefanos Flindris1, Nikolaos Katsoulas2, Anna Goussia3, Andreas Christos Lazaris2, Iordanis Navrozoglou4, Minas Paschopoulos4, Irene Thymara2. 1. Department of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece; stefflindris@gmail.com. 2. First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Athens, Greece. 3. Department of Pathology, University Hospital of Ioannina, Ioannina, Greece. 4. Department of Obstetrics and Gynecology, University Hospital of Ioannina, Ioannina, Greece.
Abstract
BACKGROUND: The aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. MATERIALS AND METHODS: Immunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates. RESULTS: Endometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was positively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67. CONCLUSION: Our study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels.
BACKGROUND: The aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. MATERIALS AND METHODS: Immunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates. RESULTS: Endometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was positively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67. CONCLUSION: Our study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels.
Authors: Frank Alber; Svetlana Dokudovskaya; Liesbeth M Veenhoff; Wenzhu Zhang; Julia Kipper; Damien Devos; Adisetyantari Suprapto; Orit Karni-Schmidt; Rosemary Williams; Brian T Chait; Andrej Sali; Michael P Rout Journal: Nature Date: 2007-11-29 Impact factor: 49.962
Authors: Ana M Ferreira; Iina Tuominen; Sónia Sousa; Frans Gerbens; Krista van Dijk-Bos; Jan Osinga; Krista A Kooi; Bahram Sanjabi; Chris Esendam; Carla Oliveira; Peter Terpstra; Menno Hardonk; Tineke van der Sluis; Monika Zazula; Jerzy Stachura; Ate G van der Zee; Harry Hollema; Rolf H Sijmons; Lauri A Aaltonen; Raquel Seruca; Robert M W Hofstra; Helga Westers Journal: Hum Mutat Date: 2014-12 Impact factor: 4.878
Authors: Meritxell Rosell; Ekaterina Nevedomskaya; Suzan Stelloo; Jaya Nautiyal; Ariel Poliandri; Jennifer H Steel; Lodewyk F A Wessels; Jason S Carroll; Malcolm G Parker; Wilbert Zwart Journal: Cancer Res Date: 2014-08-21 Impact factor: 12.701
Authors: Aurelia Vattai; Vincent Cavailles; Sophie Sixou; Susanne Beyer; Christina Kuhn; Mina Peryanova; Helene Heidegger; Kerstin Hermelink; Doris Mayr; Sven Mahner; Christian Dannecker; Udo Jeschke; Bernd Kost Journal: Oncotarget Date: 2017-10-31